Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vimian Group ABVIMGF 70 Cash Ratio is 0.52 as of Jun. 2026, which is 4% above its 10-year median of 0.50. GuruFocus rates VIMGF with a GF Score™ of 70/100 and a GF Value™ of $2.90. The stock has 2 warning signs investors should review. Among 208 Medical Diagnostics & Research companies, Vimian Group AB ranks worse than 65.87% on this metric.
Vimian Group AB has a Cash Ratio of 0.52. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Vimian Group AB's Cash Ratio or its related term are showing as below:
VIMGF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.25 Med: 0.5 Max: 1.85
Current: 0.52
During the past 9 years, Vimian Group AB's highest Cash Ratio was 1.85. The lowest was 0.25. And the median was 0.50.
VIMGF's Cash Ratio is ranked worse than 65.87% of 208
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.965
vs VIMGF: 0.52
Vimian Group AB (OTCPK:VIMGF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Vimian Group AB Cash Ratio Related Terms
Vimian Group AB Cash Ratio Historical Data
* Premium members only.
The historical data trend for Vimian Group AB's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Vimian Group AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimian Group AB Cash Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Vimian Group AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimian Group AB (VIMGF) has a Cash Ratio of 0.52 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Vimian Group AB and its competitors. This is near median its historical median of 0.50. Over the past decade, Vimian Group AB's Cash Ratio has ranged from 0.25 to 1.85. According to the industry distribution chart, Vimian Group AB ranks #137 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 65.9%.
Is Vimian Group AB's Cash Ratio too high?
Vimian Group AB's current Cash Ratio of 0.52 is near median its 10-year median of 0.50. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 1.85. The Medical Diagnostics & Research industry median Cash Ratio is 0.97. Vimian Group AB's value of 0.52 is 46.1% below this industry median. Based on the distribution chart, Vimian Group AB ranks #137 out of 208 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Vimian Group AB has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Vimian Group AB's Cash Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimian Group AB ranks #137 out of 208 companies for Cash Ratio. This places Vimian Group AB in the lower half of its industry. The industry median Cash Ratio is 0.97. Vimian Group AB's value of 0.52 is 46.1% below this benchmark. Historically, Vimian Group AB's own Cash Ratio has ranged from 0.25 to 1.85 over the past decade. While the company's 10-year median is 0.50 vs. the industry median of 0.97, Vimian Group AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Diagnostics & Research company?
The median Cash Ratio among Medical Diagnostics & Research companies is 0.97, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimian Group AB's current Cash Ratio of 0.52 is 46.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Vimian Group AB and its competitors. For the Medical Diagnostics & Research industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimian Group AB's current Cash Ratio is 0.52, which is near median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimian Group AB stock overvalued right now?
Vimian Group AB (VIMGF) has a current Cash Ratio of 0.52. The stock's GF Value™ is $2.90, compared to a current price of $2.77 — trading 4.5% below its estimated fair value. The current Cash Ratio is 0.52, which is near median its 10-year median of 0.50 and 46.1% below the Medical Diagnostics & Research industry median of 0.97. Vimian Group AB's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Vimian Group AB (VIMGF), the current Cash Ratio is 0.52 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimian Group AB (VIMGF) Overvalued in 2026?
Based on GuruFocus' analysis, Vimian Group AB stock appears to be undervalued.
The current stock price of $2.77 is trading 4.5% below its estimated GF Value™ of $2.90.
Key valuation signals for VIMGF:
Cash Ratio: 0.52 (near median its 10-year median of 0.50)
GF Value™: $2.90 vs. price of $2.77 (4.5% below fair value)
Industry Position: 46.1% below the Medical Diagnostics & Research median (#137 of 208)
No single metric tells the full story. See the VIMGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
70GF Score
Get the complete analysis for VIMGF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIMGF has been successfully added to your 
